Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$63 Mln
P/E Ratio
--
P/B Ratio
2.91
Industry P/E
--
Debt to Equity
0.9
ROE
-0.25 %
ROCE
-0 %
Div. Yield
0 %
Book Value
1635757.42
EPS
-0.46
CFO
$45.06 Mln
EBITDA
$-2.49 Mln
Net Profit
$-46.10 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cumberland Pharmaceuticals (CPIX)
| 116.03 | 11.55 | 104.80 | 212.20 | 25.50 | 5.33 | -3.01 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cumberland Pharmaceuticals (CPIX)
| 32.10 | -20.44 | -51.82 | 58.31 | -42.72 | -14.59 | -17.98 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 62.82 | 11,346.08 | 26.54 | 8.05 | |
| 72.36 | 6,636.14 | 51.14 | 23.56 | |
| 58.27 | 11,265.03 | 378.67 | 0.76 | |
| 8.04 | 9,036.23 | -- | -3.24 |
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and... internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. Address: 1600 West End Avenue, Nashville, TN, United States, 37203 Read more
Founder, Chairman, President & CEO
Mr. A. J. Kazimi MBA
Founder, Chairman, President & CEO
Mr. A. J. Kazimi MBA
Headquarters
Nashville, TN
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cumberland Pharmaceuticals Inc (CPIX) stood at $ 75,583,410 Mln as on 31-Dec-24
The share price of Cumberland Pharmaceuticals Inc (CPIX) is $5.12 (NASDAQ) as of 24-Apr-2025 11:23 EDT. Cumberland Pharmaceuticals Inc (CPIX) has given a return of 25.5% in the last 3 years.
Cumberland Pharmaceuticals Inc (CPIX) has a market capitalisation of $ 63 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cumberland Pharmaceuticals Inc (CPIX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cumberland Pharmaceuticals Inc (CPIX) and enter the required number of quantities and click on buy to purchase the shares of Cumberland Pharmaceuticals Inc (CPIX).
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. Address: 1600 West End Avenue, Nashville, TN, United States, 37203
The CEO & director of Mr. A. J. Kazimi MBA. is Cumberland Pharmaceuticals Inc (CPIX), and CFO & Sr. VP is Mr. A. J. Kazimi MBA.
There is no promoter pledging in Cumberland Pharmaceuticals Inc (CPIX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Cumberland Pharmaceuticals Inc. (CPIX) | Ratios |
|---|---|
|
Return on equity(%)
|
-0
|
|
Operating margin(%)
|
-32.95
|
|
Net Margin(%)
|
-17.11
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cumberland Pharmaceuticals Inc (CPIX) was $0 Mln.
$-0.06
(
